REGENXBIO Inc. (RGNX) - What Are Researchers Thinking About This Stock?

Key Points

• Analysts maintain a “Moderate Buy” consensus on REGENXBIO, with nine buy ratings, one strong buy, three holds and one sell. The average 12-month price target is $23.17.
• RGNX recently traded at $6.93, down 3.2%, near the lower end of its 52-week range of $5.45 to $16.19. The company remains unprofitable, with analysts expecting a full-year loss of $3.80 per share despite its latest quarterly earnings and revenue beating estimates.
• Institutional ownership is high at 88.08%, with several major investors—including Bank of America, Bank of New York Mellon and Walleye Capital—recently establishing or increasing positions. REGENXBIO is developing gene therapies using its NAV AAV platform for serious diseases.

REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the fourteen analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $23.17.

Several brokerages have weighed in on RGNX. Weiss Ratings reissued a "sell (e+)" rating on shares of REGENXBIO in a report on Friday, September 4th. Barclays downgraded REGENXBIO from an "overweight" rating to a "hold" rating in a research report on Friday, August 7th. Robert W. Baird lowered their target price on REGENXBIO from $32.00 to $29.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 25th. Wall Street Zen upgraded REGENXBIO from a "strong sell" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of REGENXBIO in a research report on Monday, September 28th.

REGENXBIO Stock Down 3.2%

RGNX opened at $6.93 on Friday. REGENXBIO has a twelve month low of $5.45 and a twelve month high of $16.19. The company's 50-day moving average price is $8.73 and its two-hundred day moving average price is $9.06. The stock has a market cap of $457.47 million, a price-to-earnings ratio of -1.83 and a beta of 1.13.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.35. The company had revenue of $108.02 million during the quarter, compared to analyst estimates of $97.63 million. REGENXBIO had a negative net margin of 112.58% and a negative return on equity of 220.07%. As a group, sell-side analysts anticipate that REGENXBIO will post -3.80 earnings per share for the current year.

Institutional Investors Weigh In On REGENXBIO

Several large investors have recently added to or reduced their stakes in RGNX. Walleye Capital LLC purchased a new position in shares of REGENXBIO in the second quarter worth about $2,441,000. Bank of America Corp DE bought a new stake in shares of REGENXBIO in the second quarter valued at approximately $6,212,000. Bank of New York Mellon Corp bought a new stake in shares of REGENXBIO in the second quarter valued at approximately $1,608,000. Dimensional Fund Advisors LP raised its position in shares of REGENXBIO by 11.8% in the first quarter. Dimensional Fund Advisors LP now owns 1,010,381 shares of the biotechnology company's stock valued at $8,464,000 after purchasing an additional 106,530 shares during the period. Finally, Ieq Capital LLC bought a new stake in shares of REGENXBIO in the second quarter valued at approximately $1,695,000. Hedge funds and other institutional investors own 88.08% of the company's stock.

About REGENXBIO

REGENXBIO Inc is a biotechnology company focused on developing and commercializing gene therapies for serious diseases. The company's programs are based primarily on its proprietary NAV AAV Technology Platform, which uses adeno-associated virus (AAV) vectors to deliver genetic material to targeted cells. Its research has emphasized conditions affecting the central nervous system, muscles and other tissues.

REGENXBIO's pipeline has included investigational therapies such as RGX-121 for mucopolysaccharidosis type II, RGX-111 for mucopolysaccharidosis type I and RGX-202 for Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.